Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

Rhea-AI Summary

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023. The company focuses on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by abnormally elevated aldosterone. The conference call will be held on Tuesday, November 7th at 4:30 p.m. ET. A live webcast and replay of the call will be available on the company's website.

RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.

Tuesday, November 7^th @ 4:30 p.m. ET

Domestic:	1-888-886-7786
International:	1-416-764-8658
Conference ID:	27015887
Webcast:	Link

If you would like a call back, please click this link, which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:
Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

 

FAQ

When will Mineralys Therapeutics report its financial results for the third quarter of 2023?

Mineralys Therapeutics will report its financial results for the third quarter of 2023 on Tuesday, November 7, 2023.

What is the focus of Mineralys Therapeutics?

Mineralys Therapeutics is focused on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by abnormally elevated aldosterone.

When is the conference call scheduled?

The conference call is scheduled for Tuesday, November 7th at 4:30 p.m. ET.

Where can I access the live webcast and replay of the conference call?

The live webcast and replay of the conference call can be accessed on the 'News & Events' page in the Investor Relations section of the Mineralys Therapeutics website.